Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$72.88 USD

72.88
3,154,484

+0.34 (0.47%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $73.47 +0.59 (0.81%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Feb 28, 2024

by Zacks Equity Research

Companies In The Article Are: HES, CVX, M,VKTX and UNH

Andrew Rocco headshot

Beyond the "Mag 7": 3 Risk-On Market Forces

by Andrew Rocco

The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.

Brian Bolan headshot

Brian's Big Idea on Healthcare

by Brian Bolan

Big moving drug stocks and the HealthCare Innovators service at Zacks.

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

by Zacks Equity Research

Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.

Akero (AKRO) Slumps 63% on Mixed Results From NASH Study

by Zacks Equity Research

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

by Zacks Equity Research

Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

by Zacks Equity Research

Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.

Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Intercept (ICPT) to Restructure Operations, Cut Workforce

by Zacks Equity Research

Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

by Zacks Equity Research

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation

by Zacks Equity Research

Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.

Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment

by Zacks Equity Research

Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

by Zacks Equity Research

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Viking (VKTX) Announces Clinical Data for Metabolic Disorders

by Zacks Equity Research

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

Intercept (ICPT) Stock Down on FDA Committee Update on NDA

by Zacks Equity Research

Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.

Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months

by Zacks Equity Research

Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

by Zacks Equity Research

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.